Tumor-infiltrating lymphocytes (TILs) therapy with low-dose interleukin-2
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tumor-infiltrating lymphocytes (TILs) therapy with low-dose interleukin-2, covering 2019-11-08 to 2019-11-08. Get the full timeline:
Most recent: Clinical Trial Update: Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma [Phase 2]